TCGA-XF-A9SY-01A-21R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 21.02496715
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.610
- ALLOGRAFT_REJECTION+0.580
- MYC_TARGETS_V2+0.580
- E2F_TARGETS+0.550
- INFLAMMATORY_RESPONSE+0.550
- G2M_CHECKPOINT+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- MYC_TARGETS_V1+0.500
- IL6_JAK_STAT3_SIGNALING+0.490
Top 10 suppressed
- KRAS_SIGNALING_DN-0.300
- BILE_ACID_METABOLISM-0.290
- PEROXISOME-0.260
- FATTY_ACID_METABOLISM-0.230
- ESTROGEN_RESPONSE_LATE-0.160
- MYOGENESIS-0.140
- ADIPOGENESIS-0.130
- ESTROGEN_RESPONSE_EARLY-0.120
- SPERMATOGENESIS-0.100
- XENOBIOTIC_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934956 | — | — | 0.947 |
| 2 | SRR1516056 | — | — | 0.946 |
| 3 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.939 |
| 4 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.938 |
| 5 | SRR934864 | — | — | 0.937 |
| 6 | TCGA-UY-A9PB-01A-11R-A38B-07 | — | — | 0.937 |
| 7 | SRR934881 | — | — | 0.934 |
| 8 | SRR1516055 | — | — | 0.933 |
| 9 | SRR934869 | — | — | 0.930 |
| 10 | TCGA-4Z-AA86-01A-11R-A39I-07 | — | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.610 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.480 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| COMPLEMENT | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |